Green giant—a tiny chloroplast genome with mighty power to produce high‐value proteins: history and phylogeny

Abstract

Summary Free‐living cyanobacteria were entrapped by eukaryotic cells ~2 billion years ago, ultimately giving rise to chloroplasts. After a century of debate, the presence of chloroplast DNA was demonstrated in the 1960s. The first chloroplast genomes were sequenced in the 1980s, followed by ~100 vegetable, fruit, cereal, beverage, oil and starch/sugar crop chloroplast genomes in the past three decades. Foreign genes were expressed in isolated chloroplasts or intact plant cells in the late 1980s and stably integrated into chloroplast genomes, with typically maternal inheritance shown in the 1990s. Since then, chloroplast genomes conferred the highest reported levels of tolerance or resistance to biotic or abiotic stress. Although launching products with agronomic traits in important crops using this concept has been elusive, commercial products developed include enzymes used in everyday life from processing fruit juice, to enhancing water absorption of cotton fibre or removal of stains as laundry detergents and in dye removal in the textile industry. Plastid genome sequences have revealed the framework of green plant phylogeny as well as the intricate history of plastid genome transfer events to other eukaryotes. Discordant historical signals among plastid genes suggest possible variable constraints across the plastome and further understanding and mitigation of these constraints may yield new opportunities for bioengineering. In this review, we trace the evolutionary history of chloroplasts, status of autonomy and recent advances in products developed for everyday use or those advanced to the clinic, including treatment of COVID‐19 patients and SARS‐CoV‐2 vaccine.

Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates

“…Since 1980s, plants have been utilized for the development of highly valuable biopharmaceuticals either for human or veterinary applications. Plant-based expression system offers several key advantages over conventional systems in terms of production speed, cost, and safety ( Basaran and Rodríguez-Cerezo, 2008 ; Paul and Ma, 2011 ; Krenek et al, 2015 ; Yao et al, 2015 ; Burnett and Burnett, 2019 ; Shanmugaraj et al, 2020a ; Daniell et al, 2021 ). Remarkably, plant-based expression system can produce large amounts of recombinant antigens in a relatively short time period within few weeks after making the gene construct ( D’Aoust et al, 2008 , 2010 ; Rybicki, 2009 ; Vézina et al, 2009 ; Pillet et al, 2016 ; Rattanapisit et al, 2020 ; Ward et al, 2020 ).…”

Biotechnological Insights on the Expression and Production of Antimicrobial Peptides in Plants

“…Additional advantages include no risk of transgene contamination or leakage into the environment since chloroplast genes are maternally inherited [ 146 ], a neutral pH and low number of active proteases [ 148 ]. The expression of therapeutic proteins in chloroplast has been well-explored for several antigens, growth factors, interferons and many other pharmaceutical proteins [ 140 , 149 , 150 , 151 ].…”

Contributions of the international plant science community to the fight against human infectious diseases – part 1: epidemic and pandemic diseases

“…Plant biotechnology has much to offer in the fight against infectious diseases, from the provision of emergency testing infrastructure (Webb et al, 2020) to the manufacture of smallmolecule drugs, recombinant antivirals, subunit vaccines, engineered viruses and virus-like particle (VLP) vaccines, therapeutic proteins, antibodies and diagnostic reagents (Capell et al, 2020;Daniell et al, 2016Daniell et al, , 2019Daniell et al, , 2021McDonald and Holtz, 2020;Rosales-Mendoza, 2020;Tus e et al, 2020). Although plants have been used as a platform for the production of pharmaceutical proteins for more than 30 years (Fischer and Buyel, 2020;Ma et al, 2003a) (Bradley and Bryan, 2019;Kobres et al, 2019).…”